248 related articles for article (PubMed ID: 38413217)
1. Advances in targeted therapy for gastric cancer based on tumor driver genes.
Wu S; Xu P; Zhang F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 53(1):73-83. PubMed ID: 38413217
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for gastric cancer: Current status and future directions (Review).
Yuan DD; Zhu ZX; Zhang X; Liu J
Oncol Rep; 2016 Mar; 35(3):1245-54. PubMed ID: 26718131
[TBL] [Abstract][Full Text] [Related]
3. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
[TBL] [Abstract][Full Text] [Related]
4. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy for esophagogastric cancer: targeted therapies.
Lyons TG; Ku GY
Chin Clin Oncol; 2017 Oct; 6(5):48. PubMed ID: 29129088
[TBL] [Abstract][Full Text] [Related]
6. Research progress in targeted therapies for gastric cancer.
Ye M; Xiu LJ; Ji QQ; Zhang YC; Sun YW; Zhao Y; Wang D; Li YJ; Wang XW; Yue XQ; Sun DZ
Int J Clin Pharmacol Ther; 2022 Dec; 60(12):509-514. PubMed ID: 36197788
[TBL] [Abstract][Full Text] [Related]
7. Current and Emerging Role of Monoclonal Antibody-Based First-Line Treatment in Advanced Gastro-Esophageal and Gastric Cancer.
Désilets A; Elkhoury R; Gebai A; Tehfe M
Curr Oncol; 2023 Oct; 30(10):9304-9316. PubMed ID: 37887572
[TBL] [Abstract][Full Text] [Related]
8. Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade.
Singh R; Kim WJ; Kim PH; Hong HJ
Exp Mol Med; 2013 Nov; 45(11):e52. PubMed ID: 24176949
[TBL] [Abstract][Full Text] [Related]
9. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
Fuchs CS; Tabernero J; Tomášek J; Chau I; Melichar B; Safran H; Tehfe MA; Filip D; Topuzov E; Schlittler L; Udrea AA; Campbell W; Brincat S; Emig M; Melemed SA; Hozak RR; Ferry D; Caldwell CW; Ajani JA
Br J Cancer; 2016 Oct; 115(8):974-982. PubMed ID: 27623234
[TBL] [Abstract][Full Text] [Related]
10. Molecular targeting to treat gastric cancer.
Aoyagi K; Kouhuji K; Kizaki J; Isobe T; Hashimoto K; Shirouzu K
World J Gastroenterol; 2014 Oct; 20(38):13741-55. PubMed ID: 25320512
[TBL] [Abstract][Full Text] [Related]
11. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer.
Sorokin M; Poddubskaya E; Baranova M; Glusker A; Kogoniya L; Markarova E; Allina D; Suntsova M; Tkachev V; Garazha A; Sekacheva M; Buzdin A
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32060041
[TBL] [Abstract][Full Text] [Related]
12. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers.
Rao Y; Samuels Z; Carter LM; Monette S; Panikar SS; Pereira PMR; Lewis JS
Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2220413120. PubMed ID: 36972439
[TBL] [Abstract][Full Text] [Related]
13. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function.
Yue J; Shao S; Zhou J; Luo W; Xu Y; Zhang Q; Jiang J; Zhu MM
Invest New Drugs; 2024 Feb; 42(1):106-115. PubMed ID: 38198061
[TBL] [Abstract][Full Text] [Related]
14. HER2-positive gastric cancer.
Boku N
Gastric Cancer; 2014 Jan; 17(1):1-12. PubMed ID: 23563986
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapies in Advanced Gastric Cancer.
Patel TH; Cecchini M
Curr Treat Options Oncol; 2020 Jul; 21(9):70. PubMed ID: 32725377
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy in gastric cancer.
Thiel A; Ristimäki A
APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
[TBL] [Abstract][Full Text] [Related]
17. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
[TBL] [Abstract][Full Text] [Related]
18. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
[TBL] [Abstract][Full Text] [Related]
19. [Advances in Treatment of Human Epidermal Growth Factor Receptor 2-Positve Gastric Cancer].
Wu XQ; Ge YP; Gong XL; Liu Y; Bai CM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Oct; 44(5):899-905. PubMed ID: 36325789
[TBL] [Abstract][Full Text] [Related]
20. [Novel pharmaceutical treatment approaches for gastric cancer].
Lordick F
Pathologe; 2017 Mar; 38(2):87-92. PubMed ID: 28220199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]